Literature DB >> 12639061

Responsiveness of the quality of life in epilepsy inventory (QOLIE-89) in an antiepileptic drug trial.

Sehyun Kim1, Ron D Hays, Gretchen L Birbeck, Barbara G Vickrey.   

Abstract

This study examined relationships among responsiveness indices for health-related quality of life (HRQOL) measures administered to adults with epilepsy enrolled in an antiepileptic drug trial. The Quality of Life in Epilepsy (QOLIE)-89 was completed at baseline and at a 28-week follow-up. Six responsiveness indices (effect size (ES), standardized response mean (SRM), responsiveness statistic, paired t-test, area under receiver operating characteristic curve or ROC, F-statistic) were calculated for each of the 16 QOLIE-89 scales, using two different external criteria for clinically significant change: (1) attainment of freedom from seizures with altered awareness, and (2) a two-category improvement between baseline and follow-up in a self-rating of the subject's overall condition. Spearman correlations among the six responsiveness indices for the 16 QOLIE-89 scales tended to be moderate to large (Spearman's p = 0.53-1.00; p's < 0.05 for 29 out of the 30 correlations). Rankings of the 16 scales across the two external criteria for change were similar for the responsiveness statistic (Spearman's p = 0.62; p < 0.05), but dissimilar for the other responsiveness indices (all p > 0.05). Both ES and SRM were well predicted by the other indices, except for ROC, using regression modeling. In conclusion, results using different responsiveness indices are comparable for a given external criterion. However, only the responsiveness statistic yielded robust results across two different external criteria. Responsiveness of this HRQOL measure can be reported in terms of previously established benchmarks for ESs, which can be predicted from other indices.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639061     DOI: 10.1023/a:1022209105926

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  23 in total

1.  A power primer.

Authors:  J Cohen
Journal:  Psychol Bull       Date:  1992-07       Impact factor: 17.737

2.  Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance.

Authors:  R A Deyo; R M Centor
Journal:  J Chronic Dis       Date:  1986

Review 3.  Interpretation of quality of life changes.

Authors:  E Lydick; R S Epstein
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

4.  Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research.

Authors:  M H Liang; M G Larson; K E Cullen; J A Schwartz
Journal:  Arthritis Rheum       Date:  1985-05

5.  Outcome assessment in clinical trials. Evidence for the sensitivity of a health status measure.

Authors:  R F Meenan; J J Anderson; L E Kazis; M J Egger; M Altz-Smith; C O Samuelson; R F Willkens; M A Solsky; S P Hayes; K L Blocka
Journal:  Arthritis Rheum       Date:  1984-12

6.  Responsiveness to change in health-related quality of life in a randomized clinical trial: a comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module. European Organization for Research and Treatment of Cancer.

Authors:  M R Stockler; D Osoba; P Goodwin; P Corey; I F Tannock
Journal:  J Clin Epidemiol       Date:  1998-02       Impact factor: 6.437

7.  Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam.

Authors:  J A Cramer; C Arrigo; G Van Hammée; E B Bromfield
Journal:  Epilepsy Res       Date:  2000-08       Impact factor: 3.045

Review 8.  Methods to explain the clinical significance of health status measures.

Authors:  Gordon H Guyatt; David Osoba; Albert W Wu; Kathleen W Wyrwich; Geoffrey R Norman
Journal:  Mayo Clin Proc       Date:  2002-04       Impact factor: 7.616

9.  Development of the quality of life in epilepsy inventory.

Authors:  O Devinsky; B G Vickrey; J Cramer; K Perrine; B Hermann; K Meador; R D Hays
Journal:  Epilepsia       Date:  1995-11       Impact factor: 5.864

10.  Effect sizes for interpreting changes in health status.

Authors:  L E Kazis; J J Anderson; R F Meenan
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

View more
  8 in total

1.  Comparing drug treatments in epilepsy.

Authors:  David Chadwick; Arif Shukralla; Tony Marson
Journal:  Ther Adv Neurol Disord       Date:  2009-05       Impact factor: 6.570

Review 2.  A review of subjective impact measures for use with children and adolescents with epilepsy.

Authors:  Justin Cowan; Gus A Baker
Journal:  Qual Life Res       Date:  2004-10       Impact factor: 4.147

3.  Development and validation of a quality of life instrument for patients with drug dependence: comparisons with SF-36 and WHOQOL-100.

Authors:  Chonghua Wan; Jiqian Fang; Runsheng Jiang; Jie Shen; Dan Jiang; Xin Tu; Susan Messing; Wan Tang
Journal:  Int J Nurs Stud       Date:  2011-03-11       Impact factor: 5.837

4.  Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials.

Authors:  Marian Kaldas; Puja P Khanna; Daniel E Furst; Philip J Clements; Weng Kee Wong; James R Seibold; Arnold E Postlethwaite; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2009-07-14       Impact factor: 7.580

5.  Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.

Authors:  D Khanna; D E Furst; R D Hays; G S Park; W K Wong; J R Seibold; M D Mayes; B White; F F Wigley; M Weisman; W Barr; L Moreland; T A Medsger; V D Steen; R W Martin; D Collier; A Weinstein; E V Lally; J Varga; S R Weiner; B Andrews; M Abeles; P J Clements
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

6.  A home-based, primary-care model for epilepsy care in India: Basis and design.

Authors:  Gagandeep Singh; Suman Sharma; Rajnder K Bansal; Raj K Setia; Sarit Sharma; Namita Bansal; Anuraag Chowdhury; Jatinder S Goraya; Susmita Chatterjee; Sukhpreet Kaur; Manpreet Kaur; Shivani Kalra; Josemir W Sander
Journal:  Epilepsia Open       Date:  2019-03-06

7.  SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures.

Authors:  Carlos A Brown; Eric M Cheng; Ron D Hays; Stefanie D Vassar; Barbara G Vickrey
Journal:  Qual Life Res       Date:  2009-08-28       Impact factor: 4.147

Review 8.  Patient Reported Outcome (PRO) assessment in epilepsy: a review of epilepsy-specific PROs according to the Food and Drug Administration (FDA) regulatory requirements.

Authors:  Annabel Nixon; Cicely Kerr; Katie Breheny; Diane Wild
Journal:  Health Qual Life Outcomes       Date:  2013-03-11       Impact factor: 3.186

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.